The Genetic Architecture of Type 2 Diabetes Pharmacotherapy: The Emerging Genomic Evidence

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|22|3610-3619

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.22, 2014-05, pp. : 3610-3619

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging gliptins for type 2 diabetes

By Cahn Avivit  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 2, 2013-06 ,pp. : 245-258

Informa Healthcare

Access to resources Recommend Favorite

Extending the evidence for exenatide in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1502, 2005-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D   Wilding John PH  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus

By  

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 4, 2003-12 ,pp. : 291-298

Bentham Science Publishers

Access to resources Recommend Favorite

A Pharmacotherapy Follow-Up Program in Patients with Type-2 Diabetes in Community Pharmacies in Spain

By Fornos José   Andrés N.   Andrés J.   Guerra M.   Egea Beatriz  

Pharmacy World and Science, Vol. 28, Iss. 2, 2006-04 ,pp. : 65-72

Springer Publishing Company

Access to resources Recommend Favorite